CoChat
Sign Up
Cited by 3,190Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

Open access
Solomon, Benjamin J., Mok, Tony, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico +7 more·2014·New England Journal of Medicine
DOI 10.1056/nejmoa1408440
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown. METHODS: We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-positive nonsquamous NSCLC who had received no previous systemic treatment for advanced disease. Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive intravenous chemotherapy (pemetrexed, 500 mg per square meter of body-surface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per milliliter per minute) every 3 weeks for up to six cycles. Crossover to crizotinib treatment after disease progression was permitted for patients receiving chemotherapy. The primary end point was progression-free survival as assessed by independent radiologic review. RESULTS: Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 months vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001). Objective response rates were 74% and 45%, respectively (P<0.001). Median overall survival was not reached in either group (hazard ratio for death with crizotinib, 0.82; 95% CI, 0.54 to 1.26; P=0.36); the probability of 1-year survival was 84% with crizotinib and 79% with chemotherapy. The most common adverse events with crizotinib were vision disorders, diarrhea, nausea, and edema, and the most common events with chemotherapy were nausea, fatigue, vomiting, and decreased appetite. As compared with chemotherapy, crizotinib was associated with greater reduction in lung cancer symptoms and greater improvement in quality of life. CONCLUSIONS: Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC. (Funded by Pfizer; PROFILE 1014 ClinicalTrials.gov number, NCT01154140.).

Verified 2026-10-06 · 18 references not checked yet

Integrity signals

Registry

Crossref · 10.1056/nejmoa1408440

Cites

15 of 33 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 17 cited sources checked · 0 supported · 0 flagged

  • Findingown data

    Grade 3 or 4 aminotransferase elevations occurred in 24 crizotinib patients (14%) and 4 chemotherapy patients (2%).

    “Grade 3 or 4 elevations of aminotransferase levels occurred in 24 patients in the crizotinib group (14%) and in 4 patients in the chemotherapy group (2%), but these elevations were managed primarily with dose interruptions or dose reductions.”
    Quote in the paperNot a substantial claim
  • Findingown data

    Intracranial lesions progressed or new intracranial lesions appeared in 25 crizotinib patients and 26 chemotherapy patients (15% in each group).

    “Intracranial lesions progressed or new intracranial lesions developed in 25 patients in the crizotinib group and in 26 patients in the chemotherapy group (15% each).”
    Quote in the paperNot a substantial claim
  • Findingown data

    Among crizotinib-assigned patients with progressive disease, 74 of 89 (83%) continued crizotinib beyond progression for a median of 3.0 months.

    “Among patients randomly assigned to crizotinib, 74 of 89 patients with progressive disease (83%) continued to receive crizotinib beyond disease progression for a median of 3.0 months (range, 0.7 to 22.6).”
    Quote in the paperSubstantial claim
  • Findingown data

    No deaths resulted from hepatic dysfunction.

    “No deaths from hepatic dysfunction occurred.”
    Quote in the paperNot a substantial claim
  • Findingown data

    Median overall survival was not reached in either treatment group.

    “Median overall survival was not reached in either group”
    • Also stated in: § Table 1. Baseline Characteristics in the Intention-to-Treat Population.* Figure 1 (facing page). Progression-free and Overall Survival. · plain
      “the median overall survival was not reached in either group.”
    Quote in the paperNot a substantial claim
  • May combine two claims. 28
  • Classified as probably not a substantial claim. 22

  • May combine two claims.

    Findingown data

    At data cutoff, 79 crizotinib-assigned patients (46%) and 62 chemotherapy-assigned patients who crossed over (36%) were still receiving crizotinib.

    “At data cutoff, 79 patients who had been randomly assigned to crizotinib (46%) and 62 patients assigned to chemotherapy who had crossed over to crizotinib (36%) were still receiving crizotinib therapy.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Of 172 patients assigned to crizotinib, 21 (12%) later received platinum-based chemotherapy.

    “Of the 172 patients assigned to crizotinib, 21 (12%) subsequently received platinum-based chemotherapy.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Median response duration was 11.3 months with crizotinib and 5.3 months with chemotherapy.

    “The median duration of re-sponse was 11.3 months and 5.3 months, respectively.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Crizotinib use was linked to larger decreases in lung-cancer symptoms and larger gains in quality of life than chemotherapy.

    “As compared with chemotherapy, crizotinib was associated with greater reduction in lung cancer symptoms and greater improvement in quality of life.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    In patients with previously untreated advanced ALK-positive nonsquamous NSCLC, crizotinib increased progression-free survival compared with pemetrexed-plus-platinum chemotherapy, with median 10.9 vs 7.0 months and HR 0.45 (95% CI 0.35-0.60; P<0.001).

    “Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 months vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001).”
    • Also stated in: § Efficacy · plain
      “The median progression-free survival was 10.9 months (95% confidence interval [CI], 8.3 to 13.9) among patients in the crizotinib group, as compared with 7.0 months (95% CI, 6.8 to 8.2) among patients in the chemotherapy group (hazard ratio”
    • Also stated in: § Table 1. Baseline Characteristics in the Intention-to-Treat Population.* Figure 1 (facing page). Progression-free and Overall Survival. · plain
      “The median progressionfree survival was 10.9 months with crizotinib as compared with 7.0 months with chemotherapy.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    One-year survival probability was 84% with crizotinib and 79% with chemotherapy.

    “The probability of 1-year survival was 84% (95% CI, 77 to 89) in the crizo-tinib group and 79% (95% CI, 71 to 84) in the chemotherapy group.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Adverse events at least 5 percentage points more frequent with chemotherapy than crizotinib were fatigue (38%), anemia (32%), and neutropenia (30%).

    “and the events for which the incidence was at least 5 percentage points higher in the chemotherapy group than in the crizotinib group were fatigue (occurring in 38% of the patients), anemia (in 32%), and neutropenia (in 30%) (Table 3).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Adverse events at least 5 percentage points more frequent with crizotinib than chemotherapy were vision disorder (71%), diarrhea (61%), and edema (49%).

    “The most common adverse events of any cause for which the incidence was at least 5 percentage points higher in the crizotinib group than in the chemotherapy group were vision disorder (occurring in 71% of the patients), diarrhea (in 61%), and edema (in 49%);”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Median treatment duration was 10.9 months in the crizotinib group and 4.1 months in the chemotherapy group.

    “The median duration of treatment was 10.9 months (range, 0.4 to 34.3) in the crizotinib group (a median of 16 cycles started [range, 1 to 50]) and 4.1 months (range, 0.7 to 6.2) in the chemotherapy group (a median of 6 cycles of chemotherapy started [range, 1 to 6]).”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Findingown data

    Three randomized patients received no study treatment, leaving 340 in the as-treated population: 171 crizotinib and 169 chemotherapy.

    “Three patients underwent randomization but received no study treatment, leaving 340 patients in the as-treated population -171 patients in the crizotinib group and 169 in the chemotherapy group (with 91 patients receiving pemetrexed-cisplatin and 78 receiving pemetrexed-carboplatin).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    In this study, grade 3 or 4 aminotransferase elevations occurred in 14% of crizotinib patients and were manageable with dose interruptions or reductions.

    “In the current study, grade 3 or 4 elevations of aminotransferase levels occurred in 14% of the patients in the crizotinib group and could be managed with dose interruptions or dose reductions.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Crizotinib was associated with a significantly higher response rate and significantly greater improvements in physical functioning, key lung-cancer symptoms (cough, dyspnea, chest pain, fatigue), and global quality of life.

    “Crizotinib treatment was also associated with a significantly higher response rate and significantly greater improvements in patient-reported measures of physical functioning, key lung-cancer symptoms (cough, dyspnea, chest pain, and fatigue), and global quality of life.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Overall survival did not differ significantly between groups at this analysis, with 26% deaths (90 of 343 randomized patients).

    “Overall survival did not differ significantly between the treatment groups at the time of this analysis, with a relatively small number of deaths reported (26%; 90 of the 343 patients who underwent randomization).”
    • Also stated in: § Discussion · plain
      “death in the crizotinib group, 0.82 (95% CI, 0.54-1.26)P=0.36 (two-sided stratified log-rank test)”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Median time to response was 1.4 months for crizotinib and 2.8 months for chemotherapy.

    “Time to response -mo § Median 1.4 2.8 Range 0.6-9.5 1.2-8.5”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Baseline characteristics and efficacy outcomes in subgroup analyses of crizotinib versus individual chemotherapy regimens resembled those in the overall population.

    “The baseline characteristics of the patients and the efficacy outcomes in subgroup analyses of crizotinib versus individual chemotherapy regimens were similar to those in the analysis of the overall population (Table S3 and Fig. S4 in the Supplementary Appendix).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Vision disorders, diarrhea, nausea, and edema were the most frequent adverse events on crizotinib, whereas nausea, fatigue, vomiting, and decreased appetite were most frequent on chemotherapy.

    “The most common adverse events with crizotinib were vision disorders, diarrhea, nausea, and edema, and the most common events with chemotherapy were nausea, fatigue, vomiting, and decreased appetite.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Median duration of response was 11.3 months for crizotinib and 5.3 months for chemotherapy.

    “Duration of response -mo ¶ Median 11.3 5.3 95% CI 8.1-13.84.1-5.8*”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Crizotinib produced significantly greater reduction from baseline than chemotherapy in pain, dyspnea, and insomnia on the QLQ-C30 and in dyspnea, cough, chest pain, arm or shoulder pain, and pain in other body parts on the QLQ-LC13 (P<0.001 for all).

    “There was a significantly greater overall reduction from baseline with crizotinib than with chemotherapy in the symptoms of pain, dyspnea, and insomnia as assessed with the use of the QLQ-C30 (Fig. 2B) and in the symptoms of dyspnea, cough, chest pain, arm or shoulder pain, and pain in other parts of the body as assessed with the use of the QLQ-LC13 (Fig. 2C) (P<0.001 for all comparisons)”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    An additional case meeting Hy's law criteria occurred in a chemotherapy-assigned patient after crossover to crizotinib.

    “An additional case that met the criteria for Hy's law occurred in a patient in the chemotherapy group after crossover to crizotinib.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Findingown data

    Median follow-up for overall survival at data cutoff was 17.4 months for crizotinib-assigned patients and 16.7 months for chemotherapy-assigned patients.

    “At the time of data cutoff, the median duration of follow-up for overall survival was 17.4 months for patients assigned to crizotinib and 16.7 months for those assigned to chemotherapy.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    The 18-month progression-free survival rate was 31% with crizotinib and 5% with chemotherapy.

    “The rate of progression-free survival at 18 months was 31% (95% CI, 23 to 39) in the crizotinib group and 5% (95% CI, 2 to 10) in the chemotherapy group.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Findingown data

    A total of 343 patients underwent randomization: 172 to crizotinib and 171 to chemotherapy.

    “Between January 2011 and July 2013, a total of 343 patients underwent randomization -172 to crizotinib and 171 to chemotherapy (intention-totreat population) (Fig. S1 in the Supplementary Appendix).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingnone given

    The results were independent of platinum type, performance status, race, and presence or absence of brain metastases.

    “These results were independent of the type of platinum treatment administered, the performance status of the patient, the patient's race, and the presence or absence of brain metastases.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Median survival had not been reached in either group, with median follow-up of 17 months.

    “It should be noted that the median survival had not been reached in either group, with a median follow-up of 17 months.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    ALK rearrangements mark a distinct NSCLC subgroup that tends to occur in younger patients who never smoked or smoked lightly and has adenocarcinoma histology.

    “They define a distinct subgroup of NSCLC that typically occurs in younger patients who have never smoked or have a history of light smoking and that has adenocarcinoma histologic characteristics.[3][4][5]”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [3][4][5]

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In phase 1 and 2 studies, crizotinib yielded objective tumor responses in about 60% of ALK-positive NSCLC patients and progression-free survival of 7 to 10 months.

    “In phase 1 and 2 studies, crizotinib treatment resulted in objective tumor responses in approximately 60% of patients with ALK-positive NSCLC and in progression-free survival of 7 to 10 months.[7][8][9]”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [7][8][9]

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Crizotinib is an oral small-molecule tyrosine kinase inhibitor targeting ALK, MET, and ROS1.

    “Crizotinib is an oral small-molecule tyrosine kinase inhibitor of ALK, MET, and ROS1 kinases.6”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [6] source

      Not checked in the free run.

  • Classified as probably not a substantial claim.

    Study design and conductown data

    The study was designed to have 85% power to detect a 50% improvement in progression-free survival (from 6 to 9 months) with 229 progression-or-death events at a one-sided alpha of 0.025.

    “We estimated that with 229 events of progression or death, the study would have 85% power to detect a 50% improvement in progression-free survival with crizotinib versus chemotherapy (from 6 months to 9 months), at a one-sided alpha level of 0.025.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    Randomization was stratified by ECOG performance status, Asian versus non-Asian race, and presence or absence of brain metastases.

    “Randomization was stratified according to ECOG performance status (0 or 1 vs. 2), Asian or non-Asian race, and presence or absence of brain metastases.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Study design and conductown data

    Efficacy endpoints were analyzed in the intention-to-treat population, which included all randomized patients.

    “Efficacy end points were measured in the intention-to-treat population, which included all patients who underwent randomization.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductcitation

    Overall survival was also analyzed with the rank-preserving structural failure time model, as prespecified, to explore crossover to crizotinib in the chemotherapy group.

    “As prespecified in the protocol, overall survival was also analyzed with the rank-preserving structural failure time model [20][21][22] to explore the effect of crossover to crizotinib in the chemotherapy group.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [20][21][22]

      Not checked in the free run.

    • Rests on an assumption: The rank-preserving structural failure time model's assumptions are valid for estimating the effect of crizotinib after crossover adjustment.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    Safety evaluations used the as-treated population, which included all patients who received at least one dose of study medication.

    “Safety evaluations were performed in the astreated population, which included all patients who received at least one dose of study medication.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Study design and conductown data

    The primary endpoint was progression-free survival as assessed by independent radiologic review.

    “The primary end point was progression-free survival (the time from randomization to RECISTdefined progression, as assessed by independent radiologic review, or death).”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Study design and conductown data

    All scans underwent central independent radiologic review by radiologists blinded to treatment assignment.

    “All scans were submitted for central independent radiologic review by radiologists who were unaware of the group assignments.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    Safety results were not adjusted for the shorter treatment duration in the chemotherapy group.

    “Safety results were not adjusted for the shorter duration of treatment in the chemotherapy group.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    In the adverse event table, only events before crossover to crizotinib were included.

    “† Only events that occurred before crossover to crizotinib are included.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Study design and conductnone given

    All analyses in the chemotherapy group except overall survival used only data collected before crossover to crizotinib.

    “All analyses in the chemotherapy group, with the exception of the analysis of overall survival, included only data collected before crossover to crizotinib.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationown data

    In previously untreated ALK-positive NSCLC, crizotinib was superior to pemetrexed-plus-platinum chemotherapy for progression-free survival, objective response rate, reduction of lung-cancer symptoms, and improvement in quality of life.

    “In conclusion, in patients with previously untreated ALK-positive NSCLC, crizotinib treatment was superior to pemetrexed-plus-platinum chemotherapy with respect to progression-free survival, objective response rate, reduction of lung-cancer symptoms, and improvement in quality of life.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    Responses could not be evaluated in four patients in each group because of early death.

    “† Responses could not be evaluated in 4 patients in each group because of early death.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    The efficacy of pemetrexed-based first-line chemotherapy in ALK-positive NSCLC has been documented, supporting its selection as the comparator.

    “The efficacy of pemetrexed-based first-line chemotherapy has since been documented in ALK-positive NSCLC, 29,30 a finding that supports this selection.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [29] source

      Not checked in the free run.

    • cites [30] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    The safety profile of crizotinib was consistent with earlier reports in previously treated advanced ALK-positive NSCLC and differed from chemotherapy.

    “The safety profile of crizotinib was consistent with that reported earlier in patients with previously treated advanced ALK-positive NSCLC 10 and differed from that observed with chemotherapy.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [10] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductnone given

    Each participating center's institutional review board or ethics committee approved the protocol, which followed international ethical guidelines, Good Clinical Practice, the Declaration of Helsinki, and local laws.

    “The protocol was approved by the institutional review board or independent ethics committee at each participating center and complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    Adverse event rates were not adjusted for differences in treatment duration.

    “* Adverse events are listed here if they were reported in 15% or more of patients in either treatment group; rates were not adjusted for differences in treatment duration.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    Patient-reported outcomes were evaluated in intention-to-treat patients who had a baseline assessment and at least one post-baseline assessment.

    “Patient-reported outcomes were evaluated in patients in the intention-to-treat population who also had a baseline assessment and at least one post-baseline assessment.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductown data

    Tumor responses were assessed with RECIST version 1.1 and confirmed by independent radiologic review.

    “Tumor responses were assessed with the use of Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, and were confirmed by independent radiologic review.”
    Quote in the paperSubstantial claim
45 of 45

  • The paper relies on this without support.

    The rank-preserving structural failure time model's assumptions are valid for estimating the effect of crizotinib after crossover adjustment.

    “As prespecified in the protocol, overall survival was also analyzed with the rank-preserving structural failure time model [20][21][22] to explore the effect of crossover to crizotinib in the chemotherapy group.”
    “After adjustment for crossover with the rank-preserving structural failure time model, the hazard ratio for death with crizotinib was 0.60 (95% CI, 0.27 to 1.42)”

  • The paper relies on this without support.

    Most advanced ALK-positive NSCLCs have nonsquamous histologic characteristics.

    “Given that most advanced ALK-positive NSCLCs have nonsquamous histologic characteristics, pemetrexed in combination with cisplatin or carboplatin was selected as the standard chemotherapy for this trial.”
2 of 2

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Iyer, S., Reisman, A., Wilner, K. D., Tursi, J., & Blackhall, F.
Affiliations
  • Chinese University of Hong Kong (HK)
  • Seoul National University Hospital (KR)
  • Kindai University (JP)
  • Florida Hospital Cancer Institute (US)
  • Vall d'Hebron Hospital Universitari (ES)
  • Ospedale di Livorno (IT)
  • Pfizer (United States) (US)
  • University of Manchester (GB)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2014-12-04
Volume
371
Issue
23
Pages
2167-2177
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1408440
OpenAlex
W2099530756
Cited by
3,190
References
33
Citations by year
2026: 92 · 2025: 142 · 2024: 185 · 2023: 220 · 2022: 256 · 2021: 296 · 2020: 302 · 2019: 363 · 2018: 365 · 2017: 375 · 2016: 347 · 2015: 233 · 2014: 10 · 2013: 1 · 2012: 1
FWCI
258.39
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Digital Access to Libraries (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
  • Research Explorer (The University of Manchester) (submittedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
crizotinib, ALK-positive non-small cell lung cancer, anaplastic lymphoma kinase, ALK inhibitors, first-line therapy, progression-free survival, overall survival, objective response rate, quality of life, adverse events
MeSH terms
Pemetrexed, Crizotinib, Anaplastic Lymphoma Kinase, Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Pyrazoles, Pyridines, Carboplatin, Disease-Free Survival, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-06.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-06.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review